Ranbaxy faces more trouble in US

In addition to the US drug regulator, Food and Drug Administration, and rival pharma majors that appear keen to launch litigation against Indian company Ranbaxy, a US citizen has joined the......

Ranbaxy launches GSK's blockbuster drug in US

In a move that will help Ranbaxy boost its revenues from the US in the next six months, the company has launched the generic version of GlaxoSmithKline's blockbuster medicine Valtrex (valacyclovir......

Peace on patents to boost Ranbaxy

Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. The numbers......

Sensex ends up 77 points, Ranbaxy zooms 10%

The Sensex opened with a positive gap of 69 points at 15,768, and zoomed to 15,812 in morning deals. Profit-taking at higher levels saw the index slip to a low of 15,654 - down 158 points from the......